All News Releases A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

21:15 ET Carson Wins Final Bassmaster Eastern Open Of The Season On Lay Lake

Keith Carson had never seen Lay Lake before this week, but leveraging two familiar features allowed the Florida pro to win the Basspro.com Bassmaster ...


18:32 ET SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming Deadline - MESO

Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and...


17:00 ET Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of...


17:00 ET Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial...


15:30 ET Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Multiple Myeloma at 2020 ASH Annual Meeting

Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable ...


15:17 ET Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation...


15:00 ET Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020

Amgen (NASDAQ:AMGN) today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily...


15:00 ET Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study...


14:14 ET Orange County Real Estate Agent Promotes Homes To MORE Buyers For MORE Money

OC, California – If you've followed the Orange County real estate market for a while, you've undoubtedly heard of Ken Leaders as he's one of the most ...


13:45 ET Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to...


12:46 ET Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers

Three studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition report promising results in the use...


12:45 ET AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)

AbbVie (NYSE: ABBV) today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA®/VENCLYXTO®...


12:34 ET Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia

New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting ...


12:30 ET Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced clinical data from the LOXO-305 global ...


12:30 ET IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)

AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib) in combination...


12:15 ET This Is a Test From PR Newswire, Please Disregard - BB

This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test from PR Newswire. This is a test...


11:48 ET Erickson anuncia certificación FAA final de las palas compuestas del rotor principal del S-64F y el CH-54B

Erickson Incorporated, empresa líder a nivel mundial en operación, mantenimiento y fabricación de aeronaves utilitarias, anunció la certificación FAA ...


11:44 ET Erickson объявляет о завершении сертификации композитных лопастей несущего винта для вертолетов моделей S-64F и CH-54B в FAA

Компания Erickson Incorporated, являющаяся одним из ведущих в мире операторов, провайдеров технического обслуживания и производителей многоцелевых...


11:34 ET Společnost Erickson oznámila, že její kompozitní vrtulové listy S-64F a CH-54B pro hlavní rotory získaly konečnou certifikaci od Amerického federálního úřadu pro letectví (FAA)

Firma Erickson Incorporated, přední světová společnost zabývající se provozem, výrobou, opravami a údržbou letadel, oznámila, že její kompozitní...


11:10 ET Tampa General Hospital Announces Taneja Family Global Emerging Diseases Institute, First of Its Kind in Florida

Today, Tampa General Hospital celebrated the opening of the new Taneja Family Global Emerging Diseases Institute, a stand-alone facility that will...


11:00 ET Hematologists Play Vital Role in Advancing COVID-19 Research, Potential Treatments

There are now millions of cases worldwide of COVID-19 infection, caused by the new virus SARS-CoV-2. As cases continue to soar, researchers around...


10:59 ET Sale of the offshore construction & cable-lay vessel Connector

Ocean Yield ASA ("Ocean Yield" or "Company") has today entered into an agreement to sell the offshore construction and cable-lay vessel Connector to...


10:30 ET Bioniz Announces Positive Clinical Data of BNZ-1, First Anti-Cytokine Therapy to Demonstrate Efficacy in Treating Refractory Cutaneous T-Cell Lymphoma

Bioniz Therapeutics, Inc., ("Bioniz") today announced positive clinical data in an oral presentation at the 62nd ASH Annual Meeting And Exposition...


10:30 ET Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting

--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020...


10:09 ET Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas

Novartis announced analyses from two separate trials with Kymriah® (tisagenlecleucel) in patients with certain advanced lymphomas. In the interim...